257 related articles for article (PubMed ID: 23631819)
21. Platinum-based adjuvant chemotherapy on moderate- and high-risk stage I and II epithelian ovarian cancer patients. Long-term single institution experience and literature review.
García-Sáenz JA; Custodio A; Casado A; Vidart JA; Coronado PJ; Martín M; López-Tarruella S; Puente J; Fernández C; Díaz-Rubio E
Clin Transl Oncol; 2011 Feb; 13(2):121-32. PubMed ID: 21324801
[TBL] [Abstract][Full Text] [Related]
22. Weekly dose-dense paclitaxel and carboplatin in recurrent ovarian carcinoma: a phase II trial.
Shawky H; Tawfik H; Hewidy M
J Egypt Natl Canc Inst; 2014 Sep; 26(3):139-45. PubMed ID: 25150129
[TBL] [Abstract][Full Text] [Related]
23. A chemoresponse assay for prediction of platinum resistance in primary ovarian cancer.
Krivak TC; Lele S; Richard S; Secord AA; Leath CA; Brower SL; Tian C; Moore RG
Am J Obstet Gynecol; 2014 Jul; 211(1):68.e1-8. PubMed ID: 24530815
[TBL] [Abstract][Full Text] [Related]
24. Prognostic Significance of Preoperative Prognostic Nutritional Index in Epithelial Ovarian Cancer Patients Treated with Platinum-Based Chemotherapy.
Miao Y; Li S; Yan Q; Li B; Feng Y
Oncol Res Treat; 2016; 39(11):712-719. PubMed ID: 27855385
[TBL] [Abstract][Full Text] [Related]
25. Survival outcomes of recurrent epithelial ovarian cancer: experience from a Thailand northern tertiary care center.
Jansaka N; Suprasert P
Asian Pac J Cancer Prev; 2014; 15(24):10837-40. PubMed ID: 25605186
[TBL] [Abstract][Full Text] [Related]
26. Prognostic value of biomarkers related to drug resistance in patients with advanced epithelial ovarian cancer.
Kim H; Kim K; No JH; Jeon YT; Jeon HW; Kim YB
Anticancer Res; 2012 Feb; 32(2):589-94. PubMed ID: 22287749
[TBL] [Abstract][Full Text] [Related]
27. Prognostic Value and Implication for Chemotherapy Treatment of ABCB1 in Epithelial Ovarian Cancer: A Meta-Analysis.
Sun S; Cai J; Yang Q; Zhu Y; Zhao S; Wang Z
PLoS One; 2016; 11(11):e0166058. PubMed ID: 27812204
[TBL] [Abstract][Full Text] [Related]
28. Intraperitoneal chemotherapy for recurrent epithelial ovarian cancer is feasible with high completion rates, low complications, and acceptable patient outcomes.
Skaznik-Wikiel ME; Lesnock JL; McBee WC; Beriwal S; Zorn KK; Richard SD; Krivak TC; Edwards RP
Int J Gynecol Cancer; 2012 Feb; 22(2):232-7. PubMed ID: 22080886
[TBL] [Abstract][Full Text] [Related]
29. Predictive markers of chemoresistance in advanced stages epithelial ovarian carcinoma.
Bonneau C; Rouzier R; Geyl C; Cortez A; Castela M; Lis R; Daraï E; Touboul C
Gynecol Oncol; 2015 Jan; 136(1):112-20. PubMed ID: 25449309
[TBL] [Abstract][Full Text] [Related]
30. BRCA1 is both a prognostic and predictive biomarker of response to chemotherapy in sporadic epithelial ovarian cancer.
Carser JE; Quinn JE; Michie CO; O'Brien EJ; McCluggage WG; Maxwell P; Lamers E; Lioe TF; Williams AR; Kennedy RD; Gourley C; Harkin DP
Gynecol Oncol; 2011 Dec; 123(3):492-8. PubMed ID: 21920589
[TBL] [Abstract][Full Text] [Related]
31. Quantitative metabolic parameters measured on F-18 FDG PET/CT predict survival after relapse in patients with relapsed epithelial ovarian cancer.
Kim CY; Jeong SY; Chong GO; Son SH; Jung JH; Kim DH; Lee SW; Ahn BC; Lee J
Gynecol Oncol; 2015 Mar; 136(3):498-504. PubMed ID: 25557270
[TBL] [Abstract][Full Text] [Related]
32. Three-dimensional collagen type I matrix up-regulates nuclear isoforms of the microtubule associated protein tau implicated in resistance to paclitaxel therapy in ovarian carcinoma.
Gurler H; Yu Y; Choi J; Kajdacsy-Balla AA; Barbolina MV
Int J Mol Sci; 2015 Feb; 16(2):3419-33. PubMed ID: 25658796
[TBL] [Abstract][Full Text] [Related]
33. Prognostic factors for stage III epithelial ovarian cancer treated with intraperitoneal chemotherapy: a Gynecologic Oncology Group study.
Landrum LM; Java J; Mathews CA; Lanneau GS; Copeland LJ; Armstrong DK; Walker JL
Gynecol Oncol; 2013 Jul; 130(1):12-8. PubMed ID: 23578540
[TBL] [Abstract][Full Text] [Related]
34. The Glasgow Prognostic Score (GPS) is a novel prognostic indicator in advanced epithelial ovarian cancer: a multicenter retrospective study.
Zhu J; Wang H; Liu CC; Lu Y; Tang H
J Cancer Res Clin Oncol; 2016 Nov; 142(11):2339-45. PubMed ID: 27566683
[TBL] [Abstract][Full Text] [Related]
35. Retrospective analysis of the survival benefit of chemotherapy for recurrent or advanced epithelial ovarian carcinoma in patients previously treated with paclitaxel plus platinum-based chemotherapy.
Nishikawa A; Hashimoto H; Takeda M; Kontani K; Miyatake T; Mimura M; Nagamatsu M; Yokoi T
Eur J Gynaecol Oncol; 2016 Aug; 37(4):451-454. PubMed ID: 29894065
[TBL] [Abstract][Full Text] [Related]
36. MicroRNA let-7a: a potential marker for selection of paclitaxel in ovarian cancer management.
Lu L; Schwartz P; Scarampi L; Rutherford T; Canuto EM; Yu H; Katsaros D
Gynecol Oncol; 2011 Aug; 122(2):366-71. PubMed ID: 21571355
[TBL] [Abstract][Full Text] [Related]
37. Breast cancer 1 (BRCA1) protein expression as a prognostic marker in sporadic epithelial ovarian carcinoma: an NCIC CTG OV.16 correlative study.
Weberpals JI; Tu D; Squire JA; Amin MS; Islam S; Pelletier LB; O'Brien AM; Hoskins PJ; Eisenhauer EA
Ann Oncol; 2011 Nov; 22(11):2403-2410. PubMed ID: 21368065
[TBL] [Abstract][Full Text] [Related]
38. Impact of antibiotic treatment during platinum chemotherapy on survival and recurrence in women with advanced epithelial ovarian cancer.
Chambers LM; Kuznicki M; Yao M; Chichura A; Gruner M; Reizes O; Debernardo R; Rose PG; Michener C; Vargas R
Gynecol Oncol; 2020 Dec; 159(3):699-705. PubMed ID: 32950250
[TBL] [Abstract][Full Text] [Related]
39. Significance of hyaluronan binding protein (HABP1/P32/gC1qR) expression in advanced serous ovarian cancer patients.
Yu G; Wang J
Exp Mol Pathol; 2013 Feb; 94(1):210-5. PubMed ID: 22771308
[TBL] [Abstract][Full Text] [Related]
40. Alopecia as surrogate marker for chemotherapy response in patients with primary epithelial ovarian cancer: a metaanalysis of four prospective randomised phase III trials with 5114 patients.
Sehouli J; Fotopoulou C; Erol E; Richter R; Reuss A; Mahner S; Lauraine EP; Kristensen G; Herrstedt J; du Bois A; Pfisterer J
Eur J Cancer; 2015 May; 51(7):825-32. PubMed ID: 25771433
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]